| Customization: | Available |
|---|---|
| CAS No.: | 121062-08-6 |
| Formula: | C50h69n15o9 |
|
Still deciding? Get samples of US$ 1100/G
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
| Product Name | HEP-1 |
| CAS NO. | 174641-44-2 |
| Other name | N/A |
| Appearance | White powder |
| Purity | 98% HPLC |
| Application | Research peptides |
| Shelf Life | 24 Months |
| Storage | Store at a temperature of 2-8 degrees, protected from light. |
Ezrin peptides amplify adaptive immunity through the RANTES/CCL5 pathways that lead to cures of drug resistant infections due to bacteria, viruses, fungi and protozoans. Ezrin peptides simultaneously suppress chronic pro-inflammatory cytokine and chemokine signalling, leading to cures for chronic inflammatory disease of the muscular-skeletal system (for example; Ankylosing Spondylitis): inflammatory gut diseases (for example; ulcerative colitis): inflammatory liver diseases (for example; HCV induced hepatitis) and inflammatory heart disease (for example; myocarditis).
Ezrin peptide pharmaceutical technology evolved from a prototype HIV peptide vaccine program in London UK and San Antonio TX, USA, established by Dr Rupert Holms in the mid-1980s. In the early 1990s, Dr Holms discovered that the amino-acid sequence at the C-terminus of HIV gp120 mimics part of the Alpha domain of human ezrin, a protein that builds multi-protein cell signalling complexes of adhesion molecules and receptors on the cell surface; with adaptor proteins, kinases and cytoskeletal components attached to the sub-surface of the cell-membrane. Aqueous solutions of Ezrin peptides are active on mucosal membrane surfaces and seem to behave as a ligand for a surface-exposed "receptor" transition conformation of human ezrin, which causes allosteric changes in the submembrane multi-protein complex that triggers intra-cellular signaling.
){kind=link}